home / stock / rptx / rptx articles
Shares of Upstart Holdings, Inc. (NASDAQ:UPST) fell sharply during Wednesday's session after the company reported first-quarter financial resu...
Shares of RingCentral, Inc. (NYSE:RNG) rose sharply in today's pre-market trading after the company reported better-than-expected first-quarte...
Monday, Roche Holdings AG (OTC:RHHBY) announced topline data from Phase 3 STARGLO study of Columvi (glofitamab) in combination ...
NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigati...
Tuesday, Repare Therapeutics Inc (NASDAQ:RPTX) announced to regain global development and commercialization rights to camonsertib (RP-350...
The Dow Jones closed higher by over 200 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around th...
Gainers ParaZero Technologies Ltd. (NASDAQ: PRZO) shares jumped 106% to $2.3901 after the company announced an Australian regulator approved first...
News, Short Squeeze, Breakout and More Instantly...
Repare Therapeutics Inc. Company Name:
RPTX Stock Symbol:
NASDAQ Market:
Repare Therapeutics Inc. Website:
Alberta Enterprise Corporation invests US$7.5 million into Amplitude precision medicine fund Canada NewsWire AEC invests US$7.5M into Amplitude Ventures US$192M Fund II to support the growth of life science startups, establishing a full-time Amplitude presence in ...
Overall response of 18.2% in heavily pretreated patients across gastrointestinal tumors with target alterations regardless of prior irinotecan exposure Prolonged clinical benefit in patients with CRC, with 40% of irinotecan-naïve patients receiving treatment for greater than nine mon...
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the first patient has been dosed in the Company’s camonsertib monotherapy non-small cell lung cancer (NSCLC) expansion of th...